TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03108664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle opthalmic solution
Description: 1 drop in the affected eye
Study: NCT03672188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Study: NCT00782262

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: KicStart™
Description: KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: KicStart™
Description: KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
Study: NCT03857477

Intervention type: GENETIC
Intervention: Genetic SNP profiling
Description: Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

Intervention type: OTHER
Intervention: Prostate cancer screening
Description: Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.

Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MRI scan will be offered to men identified within the top 10% genetic risk score profile.

Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
Study: NCT03707574

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue
Study: NCT02315911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATE
Description: surgical removal of adenoids and tonsils

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATE
Description: surgical removal of adenoids and tonsils

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APP
Description: surgical removal of adenoids and tonsils and suturing of palatal pillars
Study: NCT02035111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianshu capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT00354913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately.
Study: NCT02392117

Intervention type: DRUG
Intervention: insulin degludec
Description: Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
Study: NCT03672188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Study: NCT01540474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 1: 10 ug FMP012 with 2 ug GLA-SE
Description: Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 2: 10 ug FMP012 with 5 ug GLA-SE
Description: E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
Description: E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled group-Challenged Only: no vaccination
Description: The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Study: NCT03302494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coherex WaveCrest® Left Atrial Appendage Occlusion System
Description: Percutaneous left atrial appendage closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Watchman® LAA Closure Device
Description: Percutaeous left atrial appendage closure
Study: NCT00547716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids - 4 grams per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study: NCT01818453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized self-help program for depression
Description: For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
Study: NCT03472118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Oxygen
Description: Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
Study: NCT01922102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: 0.5 mg ranibizumab (intravitreal injections)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: 0.5 mg ranibizumab (intravitreal injections)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT
Description: Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
Study: NCT00638508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac and Ropivacaine
Description: Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
Study: NCT00782262

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: KicStart™
Description: KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
Study: NCT00983216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
Study: NCT04238728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: silver nylon dressing will be applied daily
Study: NCT02550457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape tensioned
Description: Application of Kinesio Taping with tension in the erector spine muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape non-tensioned
Description: Application of Kinesio Taping without tension in the erector spine muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rigid Tape
Description: Application of Micropore tape in the erector spine muscles.
Study: NCT02703571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Combination treatment with LEE and TMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Combination treatment with LEE and TMT
Study: NCT01072695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: 75 mg BID x 28 days
Study: NCT00974896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
Study: NCT03781167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)
Study: NCT02442427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
Study: NCT02442427

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of 0.9% normal saline
Study: NCT02985541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
Study: NCT00060320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black cohosh

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black cohosh

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00917904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Study: NCT02168465

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: teaching self-management of an intermittent catheter
Description: Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
Study: NCT04163419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 10 mg SC
Study: NCT01072695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: 75 mg BID x 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: 75 mg BID x 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg BID x 28 days
Study: NCT04163419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanezumab
Description: Tanezumab 10 mg SC
Study: NCT01072695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg BID x 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: 40 mg BID x 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200 mg/day given BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200 mg/day given BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 ug q week
Study: NCT05190120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
Study: NCT04163419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg SC
Study: NCT00471237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret
Description: 100mg, 200mg, 300mg, 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: PTH (1-34)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Bisphosphonate
Study: NCT03061162

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulsed low dose rate radiation therapy
Description: Pulsed low dose rate 3-dimensional conformal radiation therapy
Study: NCT05190120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block
Description: Patients having ACL reconstruction, meniscus surgery and knee arthroscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.
Study: NCT01096017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler®
Description: 0.4 mg, inhalation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol pMDI
Description: 200 μg, inhalation, single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pMDI placebo pMDI
Description: Placebo pMDI 2 inhalations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pMDI placebo pMDI
Description: Placebo pMDI 2 inhalations
Study: NCT03729531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vein harvesting technique
Description: Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch vein harvesting technique
Description: The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
Study: NCT02347748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-procedure script
Description: Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-procedure script
Description: Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-extubation script
Description: Patients will be read a comfort talk script before extubation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading pre-extubation script
Description: Patients will be read a comfort talk script before extubation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading 2 scripts
Description: Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation
Study: NCT03214003

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB
Description: patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
Study: NCT01096017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Turbuhaler®
Description: Placebo Turbuhaler 1 inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Turbuhaler®
Description: Placebo Turbuhaler 1 inhalation
Study: NCT02009072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutureless and glue free limbal conjunctival autograft
Description: Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sutured limbal conjunctival autograft
Description: Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
Study: NCT03134001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patients receiving oral analgesics via the PCoA™ Acute
Description: PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
Study: NCT02059265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01699061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: 3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered with a meal twice a day on Day 1
Study: NCT03110367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Reframing Intervention
Description: Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention Control Group
Description: Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
Study: NCT02728141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
Study: NCT00912431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 administered on Day 1 of Period 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-126 administered on Day 1 of Period 2
Study: NCT02377674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Graft, Model COR-VG-001
Description: The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
Study: NCT01881867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01958944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric oxide